Patient managed clinical trial

Experiences of a long-term randomized controlled prevention trial in a maiden environment: Estonian Postmenopausal Hormone Therapy trial

Background

Preventive drugs require long-term trials to show their effectiveness or harms and often a lot of changes occur during post-marketing studies. The purpose of this article is to describe the research process in a long-term randomized controlled trial and discuss the impact and consequences of changes in the research environment.

Methods

The Estonian Postmenopausal Hormone Therapy trial (EPHT), originally planned to continue for five years, was planned in co-operation with the Women's International Study of Long-Duration Oestrogen after Menopause (WISDOM) in the UK. In addition to health outcomes, EPHT was specifically designed to study the impact of postmenopausal hormone therapy (HT) on health services utilization.

Results

After EPHT recruited in 1999–2001 the Women's Health Initiative (WHI) in the USA decided to stop the estrogen-progestin trial after a mean of 5.2 years in July 2002 because of increased risk of breast cancer and later in 2004 the estrogen-only trial because HT increased the risk of stroke, decreased the risk of hip fracture, and did not affect coronary heart disease incidence. WISDOM was halted in autumn 2002. These decisions had a major influence on EPHT.

Conclusion

Changes in Estonian society challenged EPHT to find a balance between the needs of achieving responses to the trial aims with a limited budget and simultaneously maintaining the safety of trial participants. Flexibility was the main key for success. Rapid changes are not limited only to transiting societies but are true also in developed countries and the risk must be included in planning all long-term trials.

The role of ethical and data monitoring committees in situations with emerging new data from other studies needs specification. Longer funding for preventive trials and more flexibility in budgeting are mandatory. Who should prove the effectiveness of an (old) drug for a new preventive indication? In preventive drug trials companies may donate drugs but they take a financial risk, especially with licensed drugs. Public funding is crucial to avoid commercial biases. Legislation to share the costs of large post-marketing trials as well as regulation of manufacturer's participation is needed. [ISRCTN35338757]

Compliance with oral HRT in postmenopausal women in clinical trials--meta analysis

OBJECTIVE

To assess compliance with oral hormone replacement therapy (HRT) over time in postmenopausal women in clinical trials and to examine aspects of study conduct (e.g. randomized vs. nonrandomized design) that might be associated with observed compliance rates.

METHODS

Aggregation of data from the available published studies using meta-analysis. Eligible studies had to be clinical trials reporting compliance with oral HRT among postmenopausal women and have a sample size of at least 20. MEDLINE and EMBASE databases were used through January 1998 to find studies that assessed compliance with oral HRT in postmenopausal women in clinical trials. Summary estimates of compliance, and of associations between compliance and features of study conduct, were computed allowing for clustering of data within studies.

RESULTS

Thirty reports met the inclusion criteria. Overall compliance at about 1 year on average was 83.4%. In a multivariable model, one variable, whether compliance was the primary objective of the study or not, remained statistically significant, even after adjustment for clustering (odds ratio=0.47, 95% confidence interval: 0.22-1.00, P=0.05).

CONCLUSIONS

This study supports the importance of using appropriate methods for measuring compliance, if valid estimates of compliance are a serious objective of an investigation. There has been much discussion about the need for increased medication compliance, particularly for those medications used for prevention, but the means and methods to improve compliance remain elusive.

Factors associated with the difference in score between women's and doctors' decisional conflict about hormone therapy: a multilevel regression analysis

OBJECTIVE

To explore factors associated with the difference in score between women's and doctors' decisional conflict about hormone therapy (HT).

DESIGN

Secondary analysis.

SETTING AND PARTICIPANTS

family doctors were randomized to prepare women for counselling about HT using either a decision aid or a pamphlet.

MAIN VARIABLES STUDIED

After each counselling session, decisional conflict was assessed in women and doctors using the Decisional Conflict Scale (DCS) and the Provider Decision Process Assessment Instrument (PDPAI), respectively. The difference in score between the DCS and PDPAI was computed and entered as the dependent variable in a multilevel regression analysis.

MAIN OUTCOME RESULTS

A total of 40 doctors and 167 women were included in the analysis. The intra-doctor correlation coefficient was 0.25. Factors associated with women experiencing higher decisional conflict than their doctor were: age of doctor >45 years, women who were undecided about the best choice after the counselling session, women with a university degree and women who said that their doctor usually does not give them control over treatment decision. Factors associated with doctors experiencing more decisional conflict than women were: doctors who were undecided about the quality of the decision, length of visit <30 min and women who thought that the decision was shared with their doctor.

CONCLUSION

In order to reduce the disparities between women's and doctors' decisional conflict about HT, interventions aimed at raising awareness of doctors about shared decision-making should be encouraged.